Gainers
$Puxin(NEW.US)$ rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday.
$Jasper Therapeutics(JSPR.US)$ rose 38% to $9.95 in pre-market trading. Oppenheimer initiated coverage on Jasper Therapeutics with an Outperform rating and announced a price target of $21.
$Waitr Holdings Inc(WTRH.US)$ rose 26% to $1.01 in pre-market trading after Morgan Stanley reported a 10.3% passive stake in the company.
$Kintara Therapeutics Inc(KTRA.US)$ rose 16.1% to $1.11 in pre-market trading after climbing around 15% on Tuesday.
$RLX Technology(RLX.US)$ rose 14% to $5.29 in pre-market trading after declining around 5% on Tuesday.
$Koss Corp(KOSS.US)$ rose 13.3% to $21.74 in pre-market trading after jumping 25% on Tuesday.
$Generation Income Properties(GIPR.US)$ shares rose 8.2% to $8.89 in pre-market trading after climbing 12% on Tuesday.
$DatChat(DATS.US)$ shares rose 7.3% to $16.10 in pre-market trading after gaining over 19% on Tuesday.
$Vistra Corp(VST.US)$ shares rose 7% to $19.08 in pre-market trading after the company announced a $2 billion buyback.
$Sentage Holdings Inc(SNTG.US)$ rose 5.8% to $2.74 in pre-market trading after climbing over 18% on Tuesday.
$SAP SE(SAP.US)$ rose 5.3% to $141.72 in pre-market trading after the company announced preliminary Q3 financial results and raised its FY21 guidance.
$Infosys Ltd(INFY.US)$ rose 5.1% to $23.00 in pre-market trading following quarterly results.
Losers
$Neuronetics Inc(STIM.US)$ shares fell 26.9% to $4.68 in pre-market trading after the company lowered its sales guidance. BTIG downgraded Neuronetics from Buy to Neutral.
$Regulus Therapeutics Inc(RGLS.US)$ shares fell 25% to $0.57 in pre-market trading after the company announced a strategic prioritization of its next-generation candidate, RGLS8429, for the treatment of ADPKD. The company's previous ADPKD candidate, RGLS4326, will no longer be advanced.
$CytoSorbents Corp(CTSO.US)$ shares fell 9.8% to $6.25 in pre-market trading after the company reported preliminary Q3 results and received full FDA Investigational Device Exemption approval to begin US STAR-D trial on apixaban and rivaroxaban removal by DrugSorb-ATR antithrombotic removal system during urgent cardiothoracic surgery.
$NUTRIBAND INC(NTRB.US)$ fell 8.7% to $8.86 in pre-market trading. Nutriband shares jumped 31% on Tuesday after the company announced it signed an exclusive manufacturing agreement for Diocheck visual COVID-19 antibody indicator patch.
$NRX Pharmaceuticals(NRXP.US)$ fell 7.8% to $10.06 in pre-market trading. NRX Pharmaceuticals shares jumped 61% on Tuesday after the company announced progress on the worldwide commercial scale development of ZYESAMI.
$Apollo Endosurgery Inc(APEN.US)$ fell 7.6% to $7.84 in pre-market trading after the company reported pricing of $65 million public offering of common stock.
$ZIVO BIOSCIENCE(ZIVO.US)$ fell 6.5% to $4.19 in pre-market trading after gaining over 18% on Tuesday.
$CRISPR Therapeutics AG(CRSP.US)$ shares fell 5.8% to $96.70 in pre-market trading after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies.